Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.
Phosphoinositide-3-kinase (PI3K) is an important target for cancer therapeutics due to the deregulation of its signaling pathway in a wide variety of human cancers. We describe herein a novel series of imidazo[1,2-a]pyrazines as PI3K inhibitors.
Experimental Therapeutics Program, Spanish National Cancer Research Centre (CNIO). C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
Sonia
S
Martínez González
Ana Isabel
AI
Hernández
Carmen
C
Varela
Sonsoles
S
Rodríguez-Arístegui
Rosa María
RM
Alvarez
Ana Belén
AB
García
Milagros
M
Lorenzo
Virginia
V
Rivero
Julen
J
Oyarzabal
Obdulia
O
Rabal
James R
JR
Bischoff
Maribel
M
Albarrán
Antonio
A
Cebriá
Patricia
P
Alfonso
Wolfgang
W
Link
Jesús
J
Fominaya
Joaquín
J
Pastor
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D045744:Cell Line, Tumor; D006801:Humans; D007093:Imidazoles / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D051379:Mice; D008862:Microsomes, Liver / Q000378:metabolism; D008958:Models, Molecular; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000378:metabolism; D011719:Pyrazines / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects
D000970:Antineoplastic Agents; D007093:Imidazoles; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D011719:Pyrazines; C556838:imidazo(1,2-a)pyrazine